...
首页> 外文期刊>Diagnostic cytopathology >WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
【24h】

WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.

机译:WT1,单克隆CEA,TTF1和CA125抗体可用于浆液性积液中肺,乳腺和卵巢腺癌的鉴别诊断。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions can be very difficult since they all can present as tight cell clusters. This is particularly challenging when the malignant effusion is the patient's initial presentation or when the patient has a history of more than one primary. The aim of this study is to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic adenocarcinoma from the lung, breast and ovary in serous effusions. Forty-six samples of serous effusions with their corresponding cell blocks were retrieved from our hospital computer system, including 13 BACs, 13 LACs, and 20 OACs. The diagnoses were confirmed by the surgical resection. Formalin-fixed and paraffin-embedded cell block sections were immunostained for WT1, mCEA, TTF1, and CA125. Two observers blindly reviewed the immunostained slides without knowledge of the previous clinical or histologic diagnoses. The staining intensity was graded semiquantitatively as negative, 0; weak, 1+; moderate, 2+; and strong, 3+. The percentage of positively staining cells was estimated. The distribution patterns of reactivity for WT1 and TTF1 were recorded as nuclear, and mCEA and CA125 as membranous stain. Metastatic OACs showed positive immunoreactivity to WT1 in 19/20 (95%) cases, CA125 in 20/20 (100%), and all showed negative reaction for both mCEA (0/20, 0%) and TTF1 (0/20, 0%). BAC showed positive reaction in 6/13 (46%) cases to CA125 and mCEA. Staining pattern was diffuse for CA125 and focal for mCEA. Only 2/13 (15%) were positive for WT1, while all of 13 BAC cases (0/13, 0%) were negative for TTF1. LAC showed positive immunoreactivity for TTF1 in 9/13 (69%) with a characteristic nuclear staining pattern, but only 3/13 (23%) were focally stained for WT1. In addition, 8/13 (62%) of LAC cases were positive for both CA125 and mCEA. Our results demonstrate that the WT1 stain is specific for metastatic carcinoma of ovarian primary, showing a high sensitivity. In addition, CA125 stain is very sensitive for OACs, but could be positive in about a half of LAC and BAC cases. An immunostaining pattern of positive mCEA as well as negative WT1 rules out OACs, raising the possibility of LACs and BACs. A positive TTF1 staining supports the diagnosis of metastatic carcinoma originating from lung rather than breast, while a negative TTF1 favors the diagnosis of a breast primary. Immunohistochemical studies with WT1, TTF1, and mCEA antibodies are useful in the differential diagnosis of metastatic adenocarcinomas of lung, breast, and ovary.
机译:浆液性积液的肺转移性腺癌(LAC),乳腺转移性腺癌(BAC)和卵巢转移性腺癌(OAC)之间的区别可能非常困难,因为它们都可以表现为紧密的细胞簇。当恶性积液是患者的最初表现或患者有一个以上原发性病史时,这尤其具有挑战性。这项研究的目的是评估WT1,单克隆CEA(mCEA),TTF1和CA125抗体在浆液性积液中从肺,乳腺和卵巢转移性腺癌的鉴别诊断中的实用性。从我们的医院计算机系统中检索了46例浆液性浆液样本及其相应的细胞块,包括13个BAC,13个LAC和20个OAC。手术切除证实了诊断。用福尔马林固定和石蜡包埋的细胞块切片对WT1,mCEA,TTF1和CA125进行免疫染色。两名观察员在不了解先前的临床或组织学诊断的情况下盲目检查了免疫染色的载玻片。染色强度半定量分级为阴性,0。弱,1 +;中等,2+;而且3岁以上。估计阳性染色细胞的百分比。 WT1和TTF1的反应性分布模式记录为核,mCEA和CA125记录为膜状染色。转移性OAC在19/20(95%)的病例中显示出对WT1的阳性免疫反应,在20/20(100%)的CA125中显示出阳性免疫反应,并且对mCEA(0/20,0%)和TTF1(0/20, 0%)。 BAC对CA125和mCEA的阳性反应为6/13(46%)。对于CA125,染色模式是分散的,对于mCEA,染色模式是焦点。 WT1仅2/13(15%)呈阳性,而所有13例BAC病例(0/13,0%)均为TTF1阴性。 LAC对TTF1的阳性免疫反应性为9/13(69%),具有特征性的核染色模式,但只有3/13(23%)的WT1被局部染色。此外,CA125和mCEA的LAC病例中有8/13(62%)阳性。我们的结果表明,WT1染色对卵巢原发性转移癌具有特异性,显示出很高的敏感性。此外,CA125染色对OAC非常敏感,但在大约一半的LAC和BAC病例中可能呈阳性。 mCEA阳性和WT1阴性的免疫染色模式排除了OAC,增加了LAC和BAC的可能性。阳性的TTF1染色有助于诊断源自肺而不是乳腺癌的转移性癌,而阴性的TTF1则有助于诊断乳腺癌。 WT1,TTF1和mCEA抗体的免疫组织化学研究可用于肺,乳腺和卵巢转移性腺癌的鉴别诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号